Efficacy and safety inputs of edoxaban vs. warfarin, from the... | Download Table
Study reports low rates of bleeding and VTE after 12 months of edoxaban treatment
Edoxaban May Be Effective Treatment for Atrial Fibrillation After Transcatheter Aortic Valve Replacement | Mount Sinai - New York
Comparison of Once-Daily Administration of Edoxaban and Rivaroxaban in Asian Patients with Atrial Fibrillation | Scientific Reports
Bleeding Events in a Phase II Study of Edoxaban in Patients With Atrial... | Download Table
PLOS ONE: Bleeding Risk and Mortality of Edoxaban: A Pooled Meta-Analysis of Randomized Controlled Trials
Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor | SpringerLink
Important clinical trials of apixaban, edoxaban, and betrixaban | Download Scientific Diagram
Comparison of clinical outcomes of edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonists in patients with atrial fibrillation in Germany: A real-world cohort study - International Journal of Cardiology
Edoxaban: Review of pharmacology and key phase I to III clinical trials. | Semantic Scholar
Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial | Hypertension
Edoxaban versus Warfarin after Surgical Bioprosthetic Valve Implantation
Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial - The Lancet
Video: ENVISAGE-TAVI AF Cardiology Trial Review, ESC 2021
ENNOBLE-ATE trial: an open-label, randomised, multi-centre, observational study of edoxaban for children with cardiac diseases at risk of thromboembolism | Cardiology in the Young | Cambridge Core
Factor Xa inhibitor effective and safe in AF patients with liver disease - PACE-CME
Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: A randomized clinical trial - ScienceDirect
Hokusai-VTE Clinical Trial | SAVAYSA® (edoxaban) | HCP
European Society of Cardiology - #ENVISAGE-TAVI AF trial: edoxaban is noninferior to warfarin and its analogues for adverse clinical events in patients with #AFIb after #TAVI #ESCCongress #cardiology #healthcare | Facebook
EDOSURE: Worldwide Edoxaban Clinical Research Program
Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation | NEJM
33714-2.fp.png "EFFICACY AND SAFETY OF EDOXABAN IN PATIENTS WITH ATRIAL FIBRILLATION AND ACTIVE MALIGNANCY: AN ANALYSIS OF ENGAGE AF – TIMI 48 RANDOMIZED CLINICAL TRIAL | Journal of the American College of Cardiology")
EFFICACY AND SAFETY OF EDOXABAN IN PATIENTS WITH ATRIAL FIBRILLATION AND ACTIVE MALIGNANCY: AN ANALYSIS OF ENGAGE AF – TIMI 48 RANDOMIZED CLINICAL TRIAL | Journal of the American College of Cardiology
Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease | Journal of the American College of Cardiology
